Cross Country Healthcare (CCRN) Financials

$13.78 +0.27 (+2.00%)

Closing price 05/6/2025 04:00 PM Eastern

Extended Trading

$13.77 -0.01 (-0.07%)

As of 07:25 AM Eastern

Annual Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	186	73	-15
Consolidated Net Income / (Loss)	186	73	-15
Net Income / (Loss) Continuing Operations	186	73	-15
Total Pre-Tax Income	253	103	-16
Total Operating Income	270	113	-17
Total Gross Profit	2,794	2,005	1,323
Total Revenue	2,803	2,020	1,344
Operating Revenue	2,803	2,020	1,344
Total Cost of Revenue	9.61	15	21
Other Cost of Revenue	9.61	15	21
Total Operating Expenses	2,524	1,892	1,339
Selling, General & Admin Expense	324	300	233
Depreciation Expense	13	18	18
Other Operating Expenses / (Income)	2,180	1,570	1,076
Impairment Charge	5.60	0.72	2.89
Restructuring Charge	1.86	2.61	8.55
Total Other Income / (Expense), net	-17	-9.90	0.47
Interest Expense	18	9.82	2.19
Interest & Investment Income	0.00	0.00	2.05
Other Income / (Expense), net	1.33	-0.09	0.61
Income Tax Expense	67	30	-1.84
Basic Earnings per Share	$5.02	$2.07	($0.44)
Weighted Average Basic Shares Outstanding	37.01M	35.16M	33.38M
Diluted Earnings per Share	$4.95	$2.05	($0.44)
Weighted Average Diluted Shares Outstanding	37.54M	35.48M	33.38M
Weighted Average Basic & Diluted Shares Outstanding	36.82M	34.73M	32.81M

This table shows Cross Country Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	35	36	29	21	13	9.04	2.69	-16	2.56	-3.75
Consolidated Net Income / (Loss)	35	36	29	21	13	9.04	2.69	-16	2.56	-3.75
Net Income / (Loss) Continuing Operations	35	36	29	21	13	9.04	2.69	-16	2.56	-3.75
Total Pre-Tax Income	49	43	40	30	20	13	3.69	-20	3.39	-3.91
Total Operating Income	52	48	44	35	20	13	2.92	-19	2.85	-3.43
Total Gross Profit	635	1,202	618	538	440	410	378	321	314	310
Total Revenue	636	625	623	541	442	414	379	340	315	310
Operating Revenue	636	625	623	541	442	414	379	340	315	310
Total Cost of Revenue	1.10	-577	4.91	3.13	2.36	4.17	1.29	19	1.51	-0.23
Other Cost of Revenue	1.10	-	4.91	3.13	2.36	4.17	1.29	19	1.51	-0.23
Total Operating Expenses	583	1,154	574	502	420	396	375	340	311	314
Selling, General & Admin Expense	81	81	84	79	70	68	63	60	54	56
Depreciation Expense	3.21	3.16	4.90	4.43	4.54	4.47	4.64	4.72	4.50	4.34
Other Operating Expenses / (Income)	493	1,070	484	418	345	324	306	273	251	247
Impairment Charge	3.86	-	0.00	0.53	0.19	-	0.60	0.11	0.00	2.17
Restructuring Charge	2.49	0.00	0.43	0.91	0.35	0.92	0.94	2.12	1.00	4.50
Total Other Income / (Expense), net	-3.47	-5.12	-3.68	-4.88	-0.80	-0.54	0.77	-0.36	0.54	-0.48
Interest Expense	3.50	5.33	3.69	4.87	0.67	0.59	0.46	0.57	0.55	0.61
Other Income / (Expense), net	0.03	0.21	0.01	-0.01	-0.14	0.05	1.23	0.21	-0.02	-0.82
Income Tax Expense	14	6.81	11	8.96	6.69	3.93	1.00	-3.51	0.83	-0.16
Basic Earnings per Share	$0.94	$1.00	$0.82	$0.60	$0.37	$0.28	$0.08	($0.47)	$0.08	($0.13)
Weighted Average Basic Shares Outstanding	37.10M	37.01M	35.86M	35.35M	34.95M	35.16M	34.22M	33.96M	33.02M	33.38M
Diluted Earnings per Share	$0.93	$0.99	$0.81	$0.60	$0.36	$0.28	$0.08	($0.47)	$0.08	($0.13)
Weighted Average Diluted Shares Outstanding	37.49M	37.54M	36.56M	35.52M	35.15M	35.48M	34.60M	33.96M	33.06M	33.38M
Weighted Average Basic & Diluted Shares Outstanding	37.30M	36.82M	35.93M	35.80M	35.15M	34.73M	34.77M	33.81M	32.92M	32.81M

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	2.57	13	65
Net Cash From Operating Activities	134	248	120
Net Cash From Continuing Operating Activities	134	248	120
Net Income / (Loss) Continuing Operations	186	73	-15
Consolidated Net Income / (Loss)	186	73	-15
Depreciation Expense	13	18	18
Non-Cash Adjustments To Reconcile Net Income	29	24	28
Changes in Operating Assets and Liabilities, net	-94	133	88
Net Cash From Investing Activities	-44	-14	-8.71
Net Cash From Continuing Investing Activities	-44	-14	-8.71
Purchase of Property, Plant & Equipment	-8.79	-14	-8.71
Acquisitions	-35	0.00	0.00
Other Investing Activities, net	0.09	0.20	0.00
Net Cash From Financing Activities	-88	-221	-47
Net Cash From Continuing Financing Activities	-88	-221	-47
Repayment of Debt	-1,740	-872	-18
Repurchase of Common Equity	-35	-58	-37
Issuance of Debt	1,700	721	18
Other Financing Activities, net	-13	-12	-9.54
Other Net Changes in Cash	-0.01	0.01	-0.01
Cash Interest Paid	13	7.53	1.37
Cash Income Taxes Paid	83	22	2.43

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	30	-27	-3.31	0.38	14	2.79	-12	64	-5.58	18
Net Cash From Operating Activities	141	4.32	47	119	70	12	6.01	82	7.47	24
Net Cash From Continuing Operating Activities	141	4.32	47	119	70	12	6.01	82	7.47	24
Net Income / (Loss) Continuing Operations	35	36	29	21	13	9.04	2.69	-16	2.56	-3.75
Consolidated Net Income / (Loss)	35	36	29	21	13	9.04	2.69	-16	2.56	-3.75
Depreciation Expense	3.21	3.16	4.90	4.43	4.54	4.47	4.64	4.72	4.50	4.34
Non-Cash Adjustments To Reconcile Net Income	8.95	4.90	7.43	9.81	5.98	1.15	3.42	22	0.53	2.34
Changes in Operating Assets and Liabilities, net	94	-40	5.10	84	47	-2.58	-4.74	72	-0.11	21
Net Cash From Investing Activities	-2.92	-37	-3.50	-4.00	-3.41	-2.88	-2.21	-2.85	-1.12	-2.53
Net Cash From Continuing Investing Activities	-2.92	-37	-3.50	-4.00	-3.41	-2.88	-2.21	-2.85	-1.12	-2.53
Purchase of Property, Plant & Equipment	-2.92	-2.02	-3.68	-4.00	-3.43	-2.88	-2.21	-2.85	-1.12	-2.53
Net Cash From Financing Activities	-108	6.08	-47	-115	-53	-6.42	-16	-15	-12	-4.08
Net Cash From Continuing Financing Activities	-108	6.08	-47	-115	-53	-6.42	-16	-15	-12	-4.08
Repayment of Debt	-452	-407	-358	-316	-143	-56	-14	-3.15	-0.35	-0.35
Repurchase of Common Equity	-24	-11	-32	-4.72	-15	-6.40	-6.37	-15	-12	-4.08
Issuance of Debt	376	424	347	206	112	56	14	3.15	0.35	0.35
Other Net Changes in Cash	-	-	-0.00	-	-	-	-	-	-	-0.01

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	950	681	589
Total Current Assets	677	417	335
Cash & Equivalents	3.60	17	82
Accounts Receivable	642	372	223
Prepaid Expenses	11	7.68	7.85
Current Deferred & Refundable Income Taxes	13	8.62	10
Other Current Assets	8.48	11	12
Plant, Property, & Equipment, net	20	27	29
Total Noncurrent Assets	253	237	225
Noncurrent Note & Lease Receivables	23	26	21
Goodwill	163	135	135
Intangible Assets	45	54	42
Noncurrent Deferred & Refundable Income Taxes	7.12	5.98	8.10
Other Noncurrent Operating Assets	14	15	19
Total Liabilities & Shareholders' Equity	950	681	589
Total Liabilities	498	213	170
Total Current Liabilities	279	156	120
Short-Term Debt	7.50	6.79	4.41
Accounts Payable	193	93	65
Current Employee Benefit Liabilities	73	52	48
Other Current Liabilities	6.03	4.16	3.40
Total Noncurrent Liabilities	70	57	50
Noncurrent Deferred & Payable Income Tax Liabilities	7.65	11	10
Other Noncurrent Operating Liabilities	63	47	40
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	451	468	419
Total Preferred & Common Equity	451	468	419
Total Common Equity	451	468	419
Common Stock	293	236	202
Retained Earnings	160	233	218
Accumulated Other Comprehensive Income / (Loss)	-1.39	-1.39	-1.44

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	883	921	771	708	648	603	597
Total Current Assets	660	649	506	445	387	338	337
Cash & Equivalents	30	0.29	0.67	14	5.24	70	64
Accounts Receivable	611	627	485	410	357	242	245
Prepaid Expenses	3.95	11	6.75	4.78	7.62	6.25	4.55
Current Deferred & Refundable Income Taxes	-	1.78	4.13	5.24	6.33	8.97	10
Other Current Assets	15	8.53	9.20	11	11	11	13
Plant, Property, & Equipment, net	19	23	25	26	28	29	29
Total Noncurrent Assets	204	249	241	236	233	236	232
Noncurrent Note & Lease Receivables	21	23	22	22	23	23	22
Goodwill	113	142	137	135	135	135	135
Intangible Assets	47	63	60	57	52	49	46
Noncurrent Deferred & Refundable Income Taxes	8.79	7.71	7.62	6.53	6.81	10	9.04
Other Noncurrent Operating Assets	14	14	14	15	16	18	19
Total Liabilities & Shareholders' Equity	883	921	771	708	648	603	597
Total Liabilities	460	469	301	238	180	164	173
Total Current Liabilities	277	265	216	184	128	110	121
Short-Term Debt	7.50	13	16	6.91	4.10	4.10	4.10
Accounts Payable	192	177	140	115	69	56	58
Current Employee Benefit Liabilities	71	70	56	57	52	47	54
Other Current Liabilities	6.29	5.84	4.65	4.45	3.82	3.72	3.86
Total Noncurrent Liabilities	183	204	85	55	52	54	52
Capital Lease Obligations	-	-	-	-	-	-	2.35
Noncurrent Deferred & Payable Income Tax Liabilities	0.24	8.43	9.19	9.91	11	12	11
Other Noncurrent Operating Liabilities	53	57	45	45	40	42	39
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	423	452	470	470	468	439	425
Total Preferred & Common Equity	423	452	470	470	468	439	425
Total Common Equity	423	452	470	470	468	439	425
Common Stock	297	258	255	242	229	215	204
Retained Earnings	127	195	217	229	241	225	222
Accumulated Other Comprehensive Income / (Loss)	-1.37	-1.38	-1.38	-1.39	-1.39	-1.39	-1.40

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	67.20%	-27.95%	-33.46%
EBITDA Growth	89.28%	-53.85%	-98.52%
EBIT Growth	93.62%	-58.47%	-114.44%
NOPAT Growth	43.66%	-59.88%	-114.84%
Net Income Growth	40.89%	-60.95%	-120.04%
EPS Growth	40.23%	-58.59%	-121.46%
Operating Cash Flow Growth	256.57%	85.38%	-51.66%
Free Cash Flow Firm Growth	157.33%	187.42%	-54.13%
Invested Capital Growth	24.68%	-24.29%	-25.28%
Revenue Q/Q Growth	-0.56%	-9.59%	-7.19%
EBITDA Q/Q Growth	-8.76%	-21.98%	-90.24%
EBIT Q/Q Growth	-9.26%	-25.33%	-1,149.71%
NOPAT Q/Q Growth	-16.93%	-29.75%	-40,650.06%
Net Income Q/Q Growth	-18.16%	-29.06%	-724.70%
EPS Q/Q Growth	-17.91%	-27.56%	-1,366.67%
Operating Cash Flow Q/Q Growth	137.82%	3.22%	11.26%
Free Cash Flow Firm Q/Q Growth	127.28%	25.29%	9.06%
Invested Capital Q/Q Growth	14.06%	-1.06%	-6.91%
Profitability Metrics	-	-	-
Gross Margin	99.66%	99.28%	98.41%
EBITDA Margin	10.12%	6.48%	0.14%
Operating Margin	9.63%	5.58%	-1.25%
EBIT Margin	9.67%	5.58%	-1.21%
Profit (Net Income) Margin	6.63%	3.60%	-1.08%
Tax Burden Percent	73.48%	70.59%	88.77%
Interest Burden Percent	93.32%	91.36%	100.85%
Effective Tax Rate	26.52%	29.41%	0.00%
Return on Invested Capital (ROIC)	36.43%	14.99%	-2.95%
ROIC Less NNEP Spread (ROIC-NNEP)	29.17%	5.25%	3.33%
Return on Net Nonoperating Assets (RNNOA)	13.23%	0.81%	-0.33%
Return on Equity (ROE)	49.66%	15.80%	-3.28%
Cash Return on Invested Capital (CROIC)	14.47%	42.64%	25.98%
Operating Return on Assets (OROA)	32.24%	13.81%	-2.56%
Return on Assets (ROA)	22.11%	8.91%	-2.29%
Return on Common Equity (ROCE)	49.66%	15.80%	-3.28%
Return on Equity Simple (ROE_SIMPLE)	41.19%	15.53%	-3.47%
Net Operating Profit after Tax (NOPAT)	198	80	-12
NOPAT Margin	7.07%	3.94%	-0.88%
Net Nonoperating Expense Percent (NNEP)	7.26%	9.74%	-6.29%
Return On Investment Capital (ROIC_SIMPLE)	43.21%	16.77%	-2.79%
Cost of Revenue to Revenue	0.34%	0.72%	1.59%
SG&A Expenses to Revenue	11.56%	14.87%	17.36%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	90.03%	93.70%	99.66%
Earnings before Interest and Taxes (EBIT)	271	113	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	284	131	1.94
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.19	1.70	1.43
Price to Tangible Book Value (P/TBV)	4.07	2.87	2.47
Price to Revenue (P/Rev)	0.35	0.39	0.44
Price to Earnings (P/E)	5.33	10.96	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	18.77%	9.13%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.65	1.72	1.52
Enterprise Value to Revenue (EV/Rev)	0.35	0.39	0.39
Enterprise Value to EBITDA (EV/EBITDA)	3.51	6.00	268.32
Enterprise Value to EBIT (EV/EBIT)	3.67	6.97	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.02	9.87	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.42	3.16	4.33
Enterprise Value to Free Cash Flow (EV/FCFF)	12.63	3.47	5.01
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.01	0.01
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	0.45	0.15	-0.10
Leverage Ratio	2.25	1.77	1.43
Compound Leverage Factor	2.10	1.62	1.44
Debt to Total Capital	1.63%	1.43%	1.04%
Short-Term Debt to Total Capital	1.63%	1.43%	1.04%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.37%	98.57%	98.96%
Debt to EBITDA	0.03	0.05	2.27
Net Debt to EBITDA	0.01	-0.08	-39.81
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.04	0.09	-0.37
Net Debt to NOPAT	0.02	-0.13	6.54
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.83	6.69	5.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.43	2.67	2.78
Quick Ratio	2.31	2.50	2.53
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	79	226	104
Operating Cash Flow to CapEx	1,525.72%	1,778.29%	1,378.43%
Free Cash Flow to Firm to Interest Expense	4.35	23.05	47.44
Operating Cash Flow to Interest Expense	7.40	25.31	54.90
Operating Cash Flow Less CapEx to Interest Expense	6.91	23.89	50.92
Efficiency Ratios	-	-	-
Asset Turnover	3.33	2.48	2.12
Accounts Receivable Turnover	4.94	3.98	4.51
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	157.96	85.94	47.84
Accounts Payable Turnover	0.06	0.10	0.27
Days Sales Outstanding (DSO)	73.92	91.62	80.87
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	5,749.99	3,582.05	1,343.44
Cash Conversion Cycle (CCC)	-5,676.07	-3,490.43	-1,262.57
Capital & Investment Metrics	-	-	-
Invested Capital	604	457	342
Invested Capital Turnover	5.15	3.81	3.36
Increase / (Decrease) in Invested Capital	120	-147	-116
Enterprise Value (EV)	995	786	521
Market Capitalization	991	796	598
Book Value per Share	$12.11	$13.30	$12.73
Tangible Book Value per Share	$6.53	$7.90	$7.34
Total Capital	459	474	423
Total Debt	7.50	6.79	4.41
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	3.90	-10	-77
Capital Expenditures (CapEx)	8.79	14	8.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)	402	250	137
Debt-free Net Working Capital (DFNWC)	406	268	219
Net Working Capital (NWC)	398	261	215
Net Nonoperating Expense (NNE)	12	6.93	2.75
Net Nonoperating Obligations (NNO)	153	-10	-77
Total Depreciation and Amortization (D&A)	13	18	18
Debt-free, Cash-free Net Working Capital to Revenue	14.35%	12.40%	10.22%
Debt-free Net Working Capital to Revenue	14.47%	13.25%	16.30%
Net Working Capital to Revenue	14.21%	12.91%	15.97%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$5.09	$2.07	($0.44)
Adjusted Weighted Average Basic Shares Outstanding	37.01M	35.16M	33.38M
Adjusted Diluted Earnings per Share	$5.02	$2.05	($0.44)
Adjusted Weighted Average Diluted Shares Outstanding	37.54M	35.48M	33.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.82M	34.73M	32.81M
Normalized Net Operating Profit after Tax (NOPAT)	204	82	-3.80
Normalized NOPAT Margin	7.27%	4.06%	-0.28%
Pre Tax Income Margin	9.03%	5.09%	-1.22%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	14.97	11.47	-7.43
NOPAT to Interest Expense	10.95	8.10	-5.40
EBIT Less CapEx to Interest Expense	14.48	10.05	-11.41
NOPAT Less CapEx to Interest Expense	10.46	6.68	-9.38
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	18.97%	79.38%	-256.32%

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	69.67%	-2.45%	-21.05%	-28.25%	-30.47%	-33.75%	-39.11%	-37.16%	-28.75%	-25.14%
EBITDA Growth	87.84%	-34.54%	-47.82%	-52.51%	-55.42%	-65.22%	-81.95%	-136.04%	-70.33%	-99.49%
EBIT Growth	94.62%	-36.36%	-51.67%	-55.98%	-61.37%	-72.18%	-90.52%	-153.99%	-85.96%	-131.53%
NOPAT Growth	48.19%	-49.47%	-50.17%	-55.93%	-64.21%	-76.97%	-93.37%	-154.25%	-83.88%	-125.69%
Net Income Growth	48.48%	-53.19%	-52.51%	-59.65%	-63.18%	-75.11%	-90.85%	-175.19%	-80.06%	-141.52%
EPS Growth	50.00%	-52.17%	-50.31%	-57.14%	-61.29%	-71.72%	-90.12%	-178.33%	-77.78%	-146.43%
Operating Cash Flow Growth	5,067.40%	105.89%	261.39%	557.34%	-50.00%	179.49%	-87.17%	-30.90%	-89.38%	100.71%
Free Cash Flow Firm Growth	-68.71%	59.51%	104.91%	147.22%	148.38%	297.72%	967.79%	-1.71%	20.55%	-27.48%
Invested Capital Growth	62.69%	24.68%	3.30%	-17.15%	-12.72%	-24.29%	-22.49%	-27.67%	-20.58%	-25.28%
Revenue Q/Q Growth	-15.59%	-1.75%	-0.88%	-13.17%	-18.20%	-6.39%	-8.42%	-10.39%	-7.26%	-1.64%
EBITDA Q/Q Growth	-33.56%	-6.88%	-11.18%	-18.69%	-37.63%	-27.35%	-51.22%	-262.35%	151.35%	-98.74%
EBIT Q/Q Growth	-34.68%	-7.20%	-15.23%	-19.70%	-42.68%	-33.16%	-69.38%	-557.58%	114.91%	-250.04%
NOPAT Q/Q Growth	-33.72%	8.98%	-25.39%	-22.87%	-46.18%	-29.87%	-77.21%	-730.72%	116.00%	-211.73%
Net Income Q/Q Growth	-34.22%	4.37%	-24.12%	-27.49%	-39.98%	-29.46%	-70.21%	-696.21%	115.92%	-246.89%
EPS Q/Q Growth	-33.57%	6.45%	-23.58%	-25.93%	-40.00%	-22.22%	-71.43%	-687.50%	117.02%	-262.50%
Operating Cash Flow Q/Q Growth	675.19%	-96.93%	984.84%	154.45%	-41.04%	-82.83%	-50.22%	1,270.84%	-90.93%	224.42%
Free Cash Flow Firm Q/Q Growth	40.20%	52.67%	115.68%	921.65%	-38.72%	93.41%	-11.82%	-5.95%	-24.85%	16.35%
Invested Capital Q/Q Growth	-15.04%	14.06%	-1.19%	-14.29%	-10.50%	-1.06%	0.85%	-20.02%	-1.72%	-6.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	99.83%	192.32%	99.21%	99.42%	99.47%	98.99%	99.66%	94.45%	99.52%	100.07%
EBITDA Margin	8.71%	8.26%	7.82%	7.33%	5.59%	4.33%	2.32%	-4.20%	2.33%	0.03%
Operating Margin	8.20%	7.72%	7.03%	6.51%	4.59%	3.24%	0.77%	-5.65%	0.91%	-1.11%
EBIT Margin	8.21%	7.75%	7.04%	6.51%	4.56%	3.26%	1.09%	-5.59%	0.90%	-1.37%
Profit (Net Income) Margin	5.47%	5.81%	4.73%	3.95%	2.90%	2.18%	0.71%	-4.72%	0.81%	-1.21%
Tax Burden Percent	71.44%	84.21%	73.37%	70.43%	65.70%	69.69%	72.97%	82.05%	75.39%	95.89%
Interest Burden Percent	93.30%	89.02%	91.58%	86.15%	96.71%	96.23%	88.87%	102.99%	119.67%	92.12%
Effective Tax Rate	28.56%	15.79%	26.63%	29.57%	34.30%	30.31%	27.03%	0.00%	24.61%	0.00%
Return on Invested Capital (ROIC)	38.63%	33.47%	22.98%	19.53%	13.58%	8.60%	1.87%	-14.01%	2.38%	-2.61%
ROIC Less NNEP Spread (ROIC-NNEP)	36.33%	30.94%	21.55%	16.87%	12.52%	8.15%	2.62%	12.89%	1.14%	0.48%
Return on Net Nonoperating Assets (RNNOA)	12.25%	14.03%	10.08%	4.95%	1.40%	1.26%	0.43%	-0.27%	-0.08%	-0.05%
Return on Equity (ROE)	50.88%	47.50%	33.06%	24.48%	14.98%	9.86%	2.29%	-14.28%	2.30%	-2.66%
Cash Return on Invested Capital (CROIC)	8.10%	14.47%	25.18%	42.84%	36.42%	42.64%	34.62%	34.12%	22.95%	25.98%
Operating Return on Assets (OROA)	32.98%	25.83%	20.23%	18.47%	12.81%	8.06%	2.48%	-12.82%	1.99%	-2.90%
Return on Assets (ROA)	21.98%	19.36%	13.59%	11.21%	8.14%	5.41%	1.61%	-10.83%	1.80%	-2.56%
Return on Common Equity (ROCE)	50.88%	47.50%	33.06%	24.48%	14.98%	9.86%	2.29%	-14.28%	2.30%	-2.66%
Return on Equity Simple (ROE_SIMPLE)	53.76%	0.00%	34.50%	26.44%	21.80%	0.00%	9.80%	1.93%	-0.42%	0.00%
Net Operating Profit after Tax (NOPAT)	37	41	32	25	13	9.36	2.13	-13	2.15	-2.40
NOPAT Margin	5.86%	6.50%	5.16%	4.58%	3.02%	2.26%	0.56%	-3.96%	0.68%	-0.78%
Net Nonoperating Expense Percent (NNEP)	2.30%	2.54%	1.43%	2.66%	1.06%	0.45%	-0.75%	-26.90%	1.24%	-3.08%
Return On Investment Capital (ROIC_SIMPLE)	-	8.85%	-	-	-	1.97%	-	-	-	-0.57%
Cost of Revenue to Revenue	0.17%	-92.32%	0.79%	0.58%	0.53%	1.01%	0.34%	5.55%	0.48%	-0.07%
SG&A Expenses to Revenue	12.69%	12.90%	13.53%	14.60%	15.74%	16.30%	16.68%	17.73%	17.23%	17.93%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	91.62%	184.61%	92.18%	92.91%	94.88%	95.75%	98.89%	100.10%	98.61%	101.18%
Earnings before Interest and Taxes (EBIT)	52	48	44	35	20	13	4.15	-19	2.83	-4.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	55	52	49	40	25	18	8.79	-14	7.33	0.09
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.57	2.19	1.82	2.15	1.89	1.70	1.41	1.10	1.07	1.43
Price to Tangible Book Value (P/TBV)	4.13	4.07	3.32	3.69	3.20	2.87	2.34	1.89	1.87	2.47
Price to Revenue (P/Rev)	0.38	0.35	0.31	0.42	0.40	0.39	0.37	0.31	0.31	0.44
Price to Earnings (P/E)	4.77	5.33	5.27	8.11	8.67	10.96	14.34	56.67	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	20.95%	18.77%	18.97%	12.33%	11.54%	9.13%	6.97%	1.76%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.25	1.65	1.61	2.04	1.90	1.72	1.41	1.11	1.08	1.52
Enterprise Value to Revenue (EV/Rev)	0.42	0.35	0.37	0.43	0.39	0.39	0.37	0.26	0.27	0.39
Enterprise Value to EBITDA (EV/EBITDA)	3.83	3.51	4.01	5.31	5.24	6.00	7.21	11.16	19.96	268.32
Enterprise Value to EBIT (EV/EBIT)	3.99	3.67	4.27	5.77	5.84	6.97	8.99	22.02	256.17	0.00
Enterprise Value to NOPAT (EV/NOPAT)	4.99	5.02	5.77	7.69	7.77	9.87	13.24	46.59	13,629.97	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	21.14	7.42	4.63	3.39	3.66	3.16	3.16	2.43	3.68	4.33
Enterprise Value to Free Cash Flow (EV/FCFF)	34.39	12.63	6.51	4.32	4.87	3.47	3.55	2.74	4.17	5.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.32	0.02	0.33	0.10	0.01	0.01	0.01	0.01	0.02	0.01
Long-Term Debt to Equity	0.31	0.00	0.31	0.07	0.00	0.00	0.00	0.00	0.01	0.00
Financial Leverage	0.34	0.45	0.47	0.29	0.11	0.15	0.16	-0.02	-0.07	-0.10
Leverage Ratio	2.19	2.25	2.27	1.94	1.78	1.77	1.71	1.51	1.46	1.43
Compound Leverage Factor	2.05	2.00	2.08	1.67	1.72	1.71	1.52	1.56	1.75	1.32
Debt to Total Capital	24.51%	1.63%	25.04%	9.05%	1.45%	1.43%	0.87%	0.93%	1.50%	1.04%
Short-Term Debt to Total Capital	1.34%	1.63%	2.07%	3.06%	1.45%	1.43%	0.87%	0.93%	0.95%	1.04%
Long-Term Debt to Total Capital	23.17%	0.00%	22.96%	5.99%	0.00%	0.00%	0.00%	0.00%	0.54%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	75.49%	98.37%	74.96%	90.95%	98.55%	98.57%	99.13%	99.07%	98.50%	98.96%
Debt to EBITDA	0.44	0.03	0.62	0.24	0.04	0.05	0.05	0.11	0.32	2.27
Net Debt to EBITDA	0.34	0.01	0.62	0.23	-0.04	-0.08	-0.01	-1.76	-2.90	-39.81
Long-Term Debt to EBITDA	0.42	0.00	0.57	0.16	0.00	0.00	0.00	0.00	0.12	0.00
Debt to NOPAT	0.57	0.04	0.90	0.34	0.06	0.09	0.08	0.46	221.48	-0.37
Net Debt to NOPAT	0.45	0.02	0.89	0.34	-0.07	-0.13	-0.02	-7.34	-1,977.54	6.54
Long-Term Debt to NOPAT	0.54	0.00	0.82	0.23	0.00	0.00	0.00	0.00	80.65	0.00
Altman Z-Score	5.53	5.05	4.87	6.16	6.38	6.21	5.95	5.25	4.97	5.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	2.43	2.45	2.34	2.43	2.67	3.02	3.07	2.79	2.78
Quick Ratio	2.32	2.31	2.37	2.25	2.31	2.50	2.82	2.83	2.56	2.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-167	-79	13	132	81	156	138	129	97	113
Operating Cash Flow to CapEx	4,824.25%	213.54%	1,274.20%	2,984.18%	2,052.88%	419.97%	271.99%	2,892.28%	664.59%	957.49%
Free Cash Flow to Firm to Interest Expense	-47.69	-14.81	3.49	27.04	120.65	266.40	297.98	227.94	176.91	186.20
Operating Cash Flow to Interest Expense	40.20	0.81	12.70	24.48	105.10	20.60	13.01	145.07	13.58	39.86
Operating Cash Flow Less CapEx to Interest Expense	39.37	0.43	11.70	23.66	99.98	15.70	8.23	140.06	11.54	35.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	4.02	3.33	2.87	2.84	2.81	2.48	2.26	2.29	2.22	2.12
Accounts Receivable Turnover	6.18	4.94	4.05	4.09	4.37	3.98	3.61	4.33	4.42	4.51
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	168.64	157.96	132.73	112.69	99.69	85.94	69.27	58.48	52.43	47.84
Accounts Payable Turnover	14.23	0.06	12.79	9.72	10.45	0.10	12.74	16.20	18.25	0.27
Days Sales Outstanding (DSO)	59.04	73.92	90.16	89.22	83.43	91.62	101.16	84.25	82.59	80.87
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	25.65	5,749.99	28.54	37.53	34.94	3,582.05	28.65	22.53	20.00	1,343.44
Cash Conversion Cycle (CCC)	33.39	-5,676.07	61.62	51.68	48.49	-3,490.43	72.51	61.72	62.59	-1,262.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	530	604	603	516	462	457	467	374	367	342
Invested Capital Turnover	6.59	5.15	4.45	4.26	4.50	3.81	3.32	3.54	3.49	3.36
Increase / (Decrease) in Invested Capital	204	120	19	-107	-67	-147	-136	-143	-95	-116
Enterprise Value (EV)	1,192	995	972	1,055	880	786	657	416	397	521
Market Capitalization	1,085	991	822	1,009	888	796	658	481	454	598
Book Value per Share	$11.06	$12.11	$12.27	$13.09	$13.12	$13.30	$13.68	$12.63	$12.56	$12.73
Tangible Book Value per Share	$6.87	$6.53	$6.72	$7.60	$7.74	$7.90	$8.21	$7.32	$7.18	$7.34
Total Capital	560	459	603	517	477	474	472	443	431	423
Total Debt	137	7.50	151	47	6.91	6.79	4.10	4.10	6.45	4.41
Total Long-Term Debt	130	0.00	138	31	0.00	0.00	0.00	0.00	2.35	0.00
Net Debt	107	3.90	151	46	-7.39	-10	-1.14	-66	-58	-77
Capital Expenditures (CapEx)	2.92	2.02	3.68	4.00	3.43	2.88	2.21	2.85	1.12	2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	360	402	396	305	254	250	258	162	156	137
Debt-free Net Working Capital (DFNWC)	391	406	396	305	269	268	263	232	220	219
Net Working Capital (NWC)	383	398	384	290	262	261	259	228	216	215
Net Nonoperating Expense (NNE)	2.48	4.31	2.70	3.44	0.53	0.32	-0.56	2.61	-0.40	1.35
Net Nonoperating Obligations (NNO)	107	153	151	46	-7.39	-10	-1.14	-66	-58	-77
Total Depreciation and Amortization (D&A)	3.21	3.16	4.90	4.43	4.54	4.47	4.64	4.72	4.50	4.34
Debt-free, Cash-free Net Working Capital to Revenue	12.78%	14.35%	14.99%	12.55%	11.38%	12.40%	14.51%	10.29%	10.77%	10.22%
Debt-free Net Working Capital to Revenue	13.86%	14.47%	15.00%	12.58%	12.02%	13.25%	14.81%	14.71%	15.19%	16.30%
Net Working Capital to Revenue	13.59%	14.21%	14.53%	11.93%	11.71%	12.91%	14.57%	14.45%	14.91%	15.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.94	$1.00	$0.82	$0.60	$0.37	$0.28	$0.08	($0.47)	$0.08	($0.13)
Adjusted Weighted Average Basic Shares Outstanding	37.10M	37.01M	35.86M	35.35M	34.95M	35.16M	34.22M	33.96M	33.02M	33.38M
Adjusted Diluted Earnings per Share	$0.93	$0.99	$0.81	$0.60	$0.36	$0.28	$0.08	($0.47)	$0.08	($0.13)
Adjusted Weighted Average Diluted Shares Outstanding	37.49M	37.54M	36.56M	35.52M	35.15M	35.48M	34.60M	33.96M	33.06M	33.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.30M	36.82M	35.93M	35.80M	35.15M	34.73M	34.77M	33.81M	32.92M	32.81M
Normalized Net Operating Profit after Tax (NOPAT)	42	41	32	26	14	10.00	3.26	-12	2.90	2.27
Normalized NOPAT Margin	6.57%	6.50%	5.21%	4.77%	3.10%	2.41%	0.86%	-3.50%	0.92%	0.73%
Pre Tax Income Margin	7.66%	6.90%	6.44%	5.61%	4.41%	3.13%	0.97%	-5.76%	1.08%	-1.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	14.92	9.09	11.87	7.22	30.14	23.00	8.98	-33.44	5.15	-6.99
NOPAT to Interest Expense	10.66	7.62	8.71	5.09	19.94	15.96	4.61	-23.67	3.91	-3.95
EBIT Less CapEx to Interest Expense	14.09	8.71	10.88	6.40	25.02	18.09	4.20	-38.46	3.11	-11.15
NOPAT Less CapEx to Interest Expense	9.82	7.24	7.71	4.27	14.82	11.06	-0.17	-28.69	1.87	-8.12
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	10.71%	18.97%	43.00%	57.71%	60.74%	79.38%	70.31%	500.28%	-2,245.67%	-256.32%

Frequently Asked Questions About Cross Country Healthcare's Financials

When does Cross Country Healthcare's fiscal year end?

According to the most recent income statement we have on file, Cross Country Healthcare's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cross Country Healthcare's net income changed over the last 2 years?

Cross Country Healthcare's net income appears to be on a downward trend, with a most recent value of -$14.56 million in 2024, falling from $185.98 million in 2022. The previous period was $72.63 million in 2023. See Cross Country Healthcare's forecast for analyst expectations on what’s next for the company.

What is Cross Country Healthcare's operating income?

Cross Country Healthcare's total operating income in 2024 was -$16.87 million, based on the following breakdown:

Total Gross Profit: $1.32 billion
Total Operating Expenses: $1.34 billion

How has Cross Country Healthcare revenue changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's total revenue changed from $2.80 billion in 2022 to $1.34 billion in 2024, a change of -52.1%.

How much debt does Cross Country Healthcare have?

Cross Country Healthcare's total liabilities were at $170.29 million at the end of 2024, a 20.2% decrease from 2023, and a 65.8% decrease since 2022.

How much cash does Cross Country Healthcare have?

In the past 2 years, Cross Country Healthcare's cash and equivalents has ranged from $3.60 million in 2022 to $81.63 million in 2024, and is currently $81.63 million as of their latest financial filing in 2024.

How has Cross Country Healthcare's book value per share changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's book value per share changed from 12.11 in 2022 to 12.73 in 2024, a change of 5.1%.

Related Companies

This page (NASDAQ:CCRN) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cross Country Healthcare (CCRN) Financials

Frequently Asked Questions About Cross Country Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cross Country Healthcare (CCRN) Financials

Annual Income Statements for Cross Country Healthcare

Quarterly Income Statements for Cross Country Healthcare

Annual Cash Flow Statements for Cross Country Healthcare

Quarterly Cash Flow Statements for Cross Country Healthcare

Annual Balance Sheets for Cross Country Healthcare

Quarterly Balance Sheets for Cross Country Healthcare

Annual Metrics and Ratios for Cross Country Healthcare

Quarterly Metrics and Ratios for Cross Country Healthcare

Frequently Asked Questions About Cross Country Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools